Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal Bacillus anthracis spore inhalation challenge

Weir, Genevieve; MacDonald, Lisa; Rajagopalan, Rajkannan; Sivko, Gloria S.; Valderas, Michelle Wright; Rayner, Jonathan O.; Berger, Bradley J.; Sammatur, Leeladhar; Stanford, Marianne M.

doi:10.1038/s41541-019-0102-z

Cited by 16 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition to vaccines based on full protein, several vaccine developers are investigating peptides antigens as vaccine candidates against COVID-19. IMV Inc. (Québec, Canada) is developing a vaccine candidate based on the IMV's DPX delivery technology and incorporating peptides targeting S protein epitopes of SARS-Cov-2 as shown previously for respiratory syncytial virus (RSV) ( 115 ) and anthrax ( 116 ). Vaxil Bio Therapeutics (Toronto, Ontario, Canada) is using the proprietary bioinformatic approach VaxHit™ to identify signal peptide domains of SARS-CoV-2 proteins as shown for mucin 1 tumor-associated antigen in mice ( 117 ) and in multiple myeloma patients ( 118 ).…”

Section: Vaccine Platform Technologiesmentioning

confidence: 99%

The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies

et al. 2020

View full text Add to dashboard Cite

There is an urgent need for effective countermeasures against the current emergence and accelerating expansion of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Induction of herd immunity by mass vaccination has been a very successful strategy for preventing the spread of many infectious diseases, hence protecting the most vulnerable population groups unable to develop immunity, for example individuals with immunodeficiencies or a weakened immune system due to underlying medical or debilitating conditions. Therefore, vaccination represents one of the most promising counter-pandemic measures to COVID-19. However, to date, no licensed vaccine exists, neither for SARS-CoV-2 nor for the closely related SARS-CoV or Middle East respiratory syndrome-CoV. In addition, a few vaccine candidates have only recently entered human clinical trials, which hampers the progress in tackling COVID-19 infection. Here, we discuss potential prophylactic interventions for SARS-CoV-2 with a focus on the challenges existing for vaccine development, and we review pre-clinical progress and ongoing human clinical trials of COVID-19 vaccine candidates. Although COVID-19 vaccine development is currently accelerated via so-called fast-track programs, vaccines may not be timely available to have an impact on the first wave of the ongoing COVID-19 pandemic. Nevertheless, COVID-19 vaccines will be essential in the future for reducing morbidity and mortality and inducing herd immunity, if SARS-CoV-2 becomes established in the population like for example influenza virus.

show abstract

Section: Vaccine Platform Technologiesmentioning

confidence: 99%

The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Streptobacillus moniliformis and Spirillum minus infect humans through rodent bites or scratches, or mucocutaneous contact with animals’ saliva, urine, or faeces [ 5 ]. Bacillus anthracis can be transmitted from infected rodents to humans through cutaneous, gastrointestinal, or inhalation routes [ 6 ]. Over the past decade, methicillin-resistant Staphylococcus aureus (MRSA), an emerging drug-resistant bacterium, has been found in the oropharynx and rectum of R. norvegicus and the oropharynx of S. murinus [ 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

Composition of gut and oropharynx bacterial communities in Rattus norvegicus and Suncus murinus in China

Xiong

et al. 2020

BMC Vet Res

View full text Add to dashboard Cite

Background Rattus norvegicus and Suncus murinus are important reservoirs of zoonotic bacterial diseases. An understanding of the composition of gut and oropharynx bacteria in these animals is important for monitoring and preventing such diseases. We therefore examined gut and oropharynx bacterial composition in these animals in China. Results Proteobacteria, Firmicutes and Bacteroidetes were the most abundant phyla in faecal and throat swab samples of both animals. However, the composition of the bacterial community differed significantly between sample types and animal species. Firmicutes exhibited the highest relative abundance in throat swab samples of R. norvegicus, followed by Proteobacteria and Bacteroidetes. In throat swab specimens of S. murinus, Proteobacteria was the predominant phylum, followed by Firmicutes and Bacteroidetes. Firmicutes showed the highest relative abundance in faecal specimens of R. norvegicus, followed by Bacteroidetes and Proteobacteria. Firmicutes and Proteobacteria had almost equal abundance in faecal specimens of S. murinus, with Bacteroidetes accounting for only 3.07%. The family Streptococcaceae was most common in throat swab samples of R. norvegicus, while Prevotellaceae was most common in its faecal samples. Pseudomonadaceae was the predominant family in throat swab samples of S. murinus, while Enterobacteriaceae was most common in faecal samples. We annotated 33.28% sequences from faecal samples of S. murinus as potential human pathogenic bacteria, approximately 3.06-fold those in R. norvegicus. Potential pathogenic bacteria annotated in throat swab samples of S. murinus were 1.35-fold those in R. norvegicus. Conclusions Bacterial composition of throat swabs and faecal samples from R. norvegicus differed from those of S. murinus. Both species carried various pathogenic bacteria, therefore both should be closely monitored in the future, especially for S. murinus.

show abstract

“…В дополнение к этим стратегиям для повышения иммуногенности и стабильности вакцин на основе rРА83 или отдельных доменов PA исследуется возможность использования различных адъювантов (74, 108). Ряд новых адъювантов находятся на стадии клинических испытаний, и накапливаются данные об их эффективности по сравнению с гидроксидом алюминия, используемым во многих вакцинах (109). Одна из главных проблем при создании субъединичных вакцин на основе rPA83 -нестабильность этого белка.…”

Section: ключевые слова: сибирская язва Bacillus Anthracis ветеринарные вакцины рекомбинантные антигеныunclassified

ANTHRAX: LIFE CYCLE, MECHANISMS OF PATHOGENESIS AND PROSPECTS IN THE DEVELOPMENT OF VETERINARY VACCINES (review)

Кондакова¹

2021

S-h. biol.

View full text Add to dashboard Cite

Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal Bacillus anthracis spore inhalation challenge

Cited by 16 publications

References 29 publications

The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies

The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies

Composition of gut and oropharynx bacterial communities in Rattus norvegicus and Suncus murinus in China

ANTHRAX: LIFE CYCLE, MECHANISMS OF PATHOGENESIS AND PROSPECTS IN THE DEVELOPMENT OF VETERINARY VACCINES (review)

Contact Info

Product

Resources

About